Company Profile

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC
BSE3059.20-21.75 (-0.71 % )
PREV CLOSE (Rs.) 3080.95
OPEN PRICE (Rs.) 3085.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 959
TODAY'S LOW / HIGH (Rs.)3050.00 3125.80
52 WK LOW / HIGH (Rs.)3000 4900
NSE3061.70 -20.75 (-0.67 % )
PREV CLOSE(Rs.) 3082.45
OPEN PRICE (Rs.) 3080.00
BID PRICE (QTY) 3061.70 (36 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 18230
TODAY'S LOW / HIGH(Rs.) 3055.00 3131.35
52 WK LOW / HIGH (Rs.)3005 4910

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.07
TTM EPS (Rs.) 33.96
P/E Ratio 90.07
Book Value (Rs.) 185.93
Face Value (Rs.) 2
MCap (Rs. in Mn) 76480.00
Price/Earning (TTM) 72.67
Price/Sales (TTM) 9.62
Price/Book (MRQ) 16.45
PAT Margin (%) 11.47
ROCE (%) 31.24
Incorporation Year : 1979

Management Info :

Narayan K Seshadri - Chairman Gagandeep Singh Bedi - Managing Director

Registered Office :

Address : Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road,
Bengaluru,
Karnataka-560045

Phone : 080 6774 8000

Registrar's Details : Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
30, Ramana Residency,4th Cross, Sampige Road,Malleswaram,Bangalore
Listing : BSE, NSE, MCX
NEWS More
27Sep09-27-2021$Astrazeneca Pharma gets import and market permission for Selumetinib 10 Mg & 25 Mg Capsule Astrazeneca Pharma gets impo

AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsule. Selumetinib 10 mg & 25 mg capsule is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN). The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

AstraZeneca Pharma India has received Import and Market Permiss..
27Sep09-27-2021$Astrazeneca Pharma India informs about updates Astrazeneca Pharma India inf
Astrazeneca Pharma India has informed that the company has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsule. Selumetinib 10 mg & 25 mg capsule is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN). The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses.

The above information is a part of company’s filings submitted to BSE.
Astrazeneca Pharma India has informed that the company hasrecei..
27Sep09-27-2021$Astrazeneca Pharma moves up on getting import and market permission for Selumetinib 10 Mg & 25 Mg Capsule Astrazeneca Pharma moves up

Astrazeneca Pharma India is currently trading at Rs. 3111.30, up by 27.30 points or 0.89% from its previous closing of Rs. 3084.00 on the BSE.

The scrip opened at Rs. 3114.00 and has touched a high and low of Rs. 3158.10 and Rs. 3100.00 respectively. So far 417 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 4900.00 on 04-Jan-2021 and a 52 week low of Rs. 3000.00 on 30-Mar-2021.

Last one week high and low of the scrip stood at Rs. 3180.00 and Rs. 3079.70 respectively. The current market cap of the company is Rs. 7710.00 crore.

The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 3.44% and 21.56% respectively.

AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsule. Selumetinib 10 mg & 25 mg capsule is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN). The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma India is currently trading at Rs. 3111.30, u..
10Aug08-10-2021$ Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s Announcement under Regulati
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform that at the Company's 42nd Annual General Meeting held on August 9, 2021, the members have approved the re-appointment of M/s Price Waterhouse & Co, Chartered Accountants LLP (Firm Registration No 304026E/E-300009) as Statutory Auditors of the Company for a second term of 5 years i.e., to hold office till the conclusion of the 47th Annual General Meeting of the Company.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and..
10Aug08-10-2021$ Appointment Of Ms. Revathy Ashok As Independent Director For A Second Term Of 5 Years Appointment Of Ms. Revathy
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform that at the Company's 42nd Annual General Meeting held on August 9, 2021, the members have approved the re-appointment of Ms. Revathy Ashok, as an Independent Director (DIN: 00057539) for a second term of 5 years i.e., with effect from December 2, 2021 till December 1, 2026. A brief profile of Ms. Revathy Ashok is enclosed. Further, in compliance with circular no. LIST/COMP/14/2018-19 and circular no. NSE/CML/2018/02 dated June 20, 2018 issued by BSE and NSE respectively, we affirm that Ms. Revathy Ashok is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. Ms. Revathy Ashok is not related to any other director of AstraZeneca Pharma India Limited.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 21
Net Profit102.42933.039999999999
Gross Profit 135.03 1270.94
Operating Profit 185.31483.13
Net Sales 1754.028135.63
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 20746.95 (0.93%)
M.Cap ( in Cr)
44085.82
Ajanta Pharma (BSE)
 2215.40 (2.45%)
M.Cap ( in Cr)
19171.13
Sanofi India (BSE)
 8117.95 (0.35%)
M.Cap ( in Cr)
18696.14
Mercury Laboratories (BSE)
 718.00 (3.16%)
M.Cap ( in Cr)
86.16
Suven Pharma (BSE)
 533.95 (1.75%)
M.Cap ( in Cr)
13592.50
Shareholding Pattern More
PROMOTERS 75 %
NON-INSTITUTION 21.55 %
MUTUAL FUNDS/UTI 0.93 %
FI/BANKS/INSURANCE 0.03 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
F & O Quotes